[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trichuris-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trichuris-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100612791","phase-2-efficacy-and-safety-of-a-single-dose-of-emodepside-compared-to-a-single-dose-of-albendazole-in-adolescents-and-adults-infected-with-trichuris-incognita-100612791",false,"NCT07258173","Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita","Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita: a Phase II, Randomized, Double Blind, Controlled Trial","EMOTI","Inclusion Criteria:\n\n* Aged 12 years and above.\n* Written informed consent signed by participant and, in the case of minors, parents\u002Fcaregivers.\n* Agree to comply with study procedures, including provision of two stool samples at the beginning (screening) and at follow-up assessment 14-21 days after treatment.\n* Having at least two slides of the quadruple Kato-Katz thick smears positive for Trichuris incognita and infection intensities of at least 48 eggs per gram (EPG).\n* Willing to be examined by a study physician prior to treatment.\n\nExclusion Criteria:\n\n* Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38 °C, severe anemia (Hb below 80g\u002Fl) upon initial clinical assessment etc.\n* History of severe acute or unmanaged severe chronic disease (i.e., condition is not as therapeutically controlled as necessary).\n* Positive malaria rapid diagnostic test (RDT) and temperature ≥ 38 °C.\n* Abnormal liver and renal function assessed by biochemical blood-based analyses.\n* Recent use of anthelmintic drugs (in the 4 weeks before treatment).\n* Known allergy to study medications and formulations (i.e. albendazole and emodepside).\n* Prescribed or taking medication with known contraindication to or interaction with study drugs.\n* Participating in other clinical trials during the study period.\n* Pregnancy or breastfeeding.","ALL","12 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this clinical trial is to compare the efficacy and safety of emodepside with the standard treatment, albendazole, in adolescents (12 years and older) and adults infected with Trichuris incognita.",[27],"Trichuris Infection",[29,30,31,32,33,34,35],"Trichuris incognita","emodepside","efficacy","safety","soil transmitted helminths","Trichuris","Côte d'Ivoire","NOT_YET_RECRUITING","2026-05-04",{"date":39,"type":40},"2026-05-08","ACTUAL",{"date":42,"type":21},"2026-05-15",{"date":44,"type":21},"2026-09-15",{"name":46,"class":47},"Jennifer Keiser","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100319204","phase-2-efficacy-of-oxfendazole-in-the-treatment-of-trichuris-trichiura-infection-in-adults-100319204","NCT03435718","Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults","An Assessor Blind, Randomized, Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults","Inclusion Criteria:\n\n1. Male or female outpatient, more than 18 years and less than 65 years of age.\n2. Written or witnessed oral informed consent has been obtained.\n3. Trichuris trichiura demonstrated in stool samples obtained during the week before enrolment: The presence of Ascaris lumbricoides, Necator americanus, Ancylostoma duodenalis or other helminths will not be a cause for exclusion.\n4. Willingness to comply with the requirements of the protocol and particularly to provide 4 stool samples, pretreatment and 7, 14 and 21 days after treatment.\n5. Female patients of child bearing potential, who are using an established method of birth control (surgically sterile, intra-uterine contraceptive device, oral contraceptives, diaphragm in combination with contraceptive cream or foam, or condom in combination with contraceptive cream or foam) may be included\n\nExclusion Criteria:\n\n1. The patient has demonstrated a previous hypersensitivity reaction to benzimidazole or other related compound.\n2. Presence of other helminths without Trichuris trichiura. Non-target species may be present and details of response will be recorded.\n3. The patient has diarrhoeal disease that would interfere with the evaluation of stool samples.\n4. The patient has received an anthelminthic in the 2 weeks prior to enrolment into the study.\n5. The patient has received an investigational drug within 30 days or 5 half-lives (whichever is longer) of the screening visit or is scheduled to receive such a drug during the study period.\n6. The patient has a concomitant infection or any other underlying disease that would compromise the diagnosis and the evaluation of the response to the study medication.\n7. The patient has a known history of renal dysfunction or plasma creatinine ≥ 1.5 times upper limit of normal for age or a known history of hepatic dysfunction or liver enzymes ≥ 1.5 times upper limit of normal.\n8. The patient is a female who is pregnant, lactating or planning a pregnancy during the study, or is not practicing any form of contraception (see inclusion criteria (4.2.5).\n9. The patient is unwilling or unable to take part in this study.\n10. The patient has previously been enrolled in the study.","18 Years","65 Years",{"count":58,"type":21},250,[24],"The main objective of this study is to provide data on the efficacy profile of different doses of oxfendazole when used in Trichuris trichiura infection. The drug will be also be examined for efficacy against other common nematodes encountered in man (Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus). The study will also provide data on the safety and tolerability of the oxfendazole in patients.",[27],[63,64,65],"oxfendazole","albendazole","Trichuris trichiura","2023-11-07",{"date":68,"type":40},"2023-11-08",{"date":70,"type":21},"2024-07",{"date":72,"type":21},"2026-10",{"name":74,"class":47},"Oxfendazole Development Group"]